Abstract
We have recently presented the synthesis of 2-amino-1,4-benzoquinones by nuclear amination of phydroquinones with primary aromatic amines using fungal laccases as catalysts. In the present report, a series of selected 2-amino-1,4-benzoquinones was tested for biological activities, such as inhibition of human 5-lipoxygenase and antiproliferative/ anti-neoplastic effects. Compound 9 (2-[4-(iso-propylphenyl)-amino]-5,6-dimethyl-1,4-benzoquinone) was identified as the most potent aminoquinone derivative, suppressing 5-lipoxygenase in intact human polymorphonuclear leukocytes as well as in crude enzyme preparations in the low micromolar range (IC50 = 6 μM). Structure-activity relationships are discussed. Of interest, the 5-lipoxygenase inhibitory properties of 2-amino-1,4-benzoquinones in intact cells correlated to the anti-neoplastic activities of the compounds in breast and urinary bladder cancer cell lines. Based on these features, bioactive 2-amino-1,4-benzoquinones may possess potential for the pharmacological treatment of diseases associated with elevated 5-lipoxygenase activity, in particular certain types of cancer.
Keywords: Aminoquinones, antineoplastic activity, lipoxygenase, cancer
Medicinal Chemistry
Title: Inhibition of Human 5-Lipoxygenase and Anti-Neoplastic Effects by 2-Amino-1,4-Benzoquinones
Volume: 2 Issue: 6
Author(s): Daniel Poeckel, Timo H.J. Niedermeyer, Hang T.L. Pham, Annett Mikolasch, Sabine Mundt, Ulrike Lindequist, Michael Lalk and Oliver Werz
Affiliation:
Keywords: Aminoquinones, antineoplastic activity, lipoxygenase, cancer
Abstract: We have recently presented the synthesis of 2-amino-1,4-benzoquinones by nuclear amination of phydroquinones with primary aromatic amines using fungal laccases as catalysts. In the present report, a series of selected 2-amino-1,4-benzoquinones was tested for biological activities, such as inhibition of human 5-lipoxygenase and antiproliferative/ anti-neoplastic effects. Compound 9 (2-[4-(iso-propylphenyl)-amino]-5,6-dimethyl-1,4-benzoquinone) was identified as the most potent aminoquinone derivative, suppressing 5-lipoxygenase in intact human polymorphonuclear leukocytes as well as in crude enzyme preparations in the low micromolar range (IC50 = 6 μM). Structure-activity relationships are discussed. Of interest, the 5-lipoxygenase inhibitory properties of 2-amino-1,4-benzoquinones in intact cells correlated to the anti-neoplastic activities of the compounds in breast and urinary bladder cancer cell lines. Based on these features, bioactive 2-amino-1,4-benzoquinones may possess potential for the pharmacological treatment of diseases associated with elevated 5-lipoxygenase activity, in particular certain types of cancer.
Export Options
About this article
Cite this article as:
Poeckel Daniel, Niedermeyer H.J. Timo, Pham T.L. Hang, Mikolasch Annett, Mundt Sabine, Lindequist Ulrike, Lalk Michael and Werz Oliver, Inhibition of Human 5-Lipoxygenase and Anti-Neoplastic Effects by 2-Amino-1,4-Benzoquinones, Medicinal Chemistry 2006; 2 (6) . https://dx.doi.org/10.2174/1573406410602060591
DOI https://dx.doi.org/10.2174/1573406410602060591 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice
Current Radiopharmaceuticals The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Integrated Analysis of mRNA-seq and miRNA-seq to Identify c-MYC, YAP1 and miR-3960 as Major Players in the Anticancer Effects of Caffeic Acid Phenethyl Ester in Human Small Cell Lung Cancer Cell Line
Current Gene Therapy An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer
Mini-Reviews in Medicinal Chemistry Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Molecular Symmetry: A Structural Property Frequently Present in New Cytotoxic and Proapoptotic Drugs
Mini-Reviews in Medicinal Chemistry Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Specific Hemosiderin Deposition in Spleen Induced by a Low Dose of Cisplatin: Altered Iron Metabolism and Its Implication as an Acute Hemosiderin Formation Model
Current Drug Metabolism Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism